Oncolytic virus synergizes with Smac mimetic compounds to induce rhabdomyosarcoma cell death in a syngeneic murine model

Oncotarget

Volumn 8, Issue 2, 2017, Pages 3495-3508

  Dobson, Christine C ^a,b   Naing, Thet ^a   Beug, Shawn T ^a   Faye, Mame D ^a   Chabot, Janelle ^a   St Jean, Martin ^a   Walker, Danielle E ^a   LaCasse, Eric C ^a   Stojdl, David F ^a,b   Korneluk, Robert G ^a,b   Holcik, Martin ^a,b  

^a CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Immunotherapy; Oncolytic virus; Rhabdomyosarcoma; Smac mimetic

Indexed keywords

ANTINEOPLASTIC AGENT; APOPTOSIS INDUCING FACTOR; APOPTOSIS INHIBITOR; GAMMA INTERFERON; INHIBITOR OF APOPTOSIS 1; INTERFERON REGULATORY FACTOR 1; INTERFERON REGULATORY FACTOR 7; N [1 CYCLOHEXYL 2 [2 [4 (4 FLUOROBENZOYL) 2 THIAZOLYL] 1 PYRROLIDINYL] 2 OXOETHYL] 2 (METHYLAMINO)PROPANAMIDE; ONCOLYTIC VIRUS; SMAC MIMETIC COMPOUND; TUMOR NECROSIS FACTOR; TUMOUR NECROSIS FACTOR LIKE WEAK INDUCER OF APOPTOSIS; UNCLASSIFIED DRUG; THIAZOLE DERIVATIVE;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELL DEATH; CELL KILLING; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIVITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; IRF1 GENE; IRF7 GENE; LONG TERM SURVIVAL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RHABDOMYOSARCOMA; SIGNAL TRANSDUCTION; TNF ALPHA GENE; TUMOR VOLUME; ANIMAL; CELL SURVIVAL; DISEASE MODEL; DRUG EFFECT; DRUG SCREENING; GENETICS; IMMUNOLOGY; METABOLISM; MOLECULAR MIMICRY; MULTIMODALITY CANCER THERAPY; ONCOLYTIC VIROTHERAPY; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; CELL DEATH; CELL LINE, TUMOR; CELL SURVIVAL; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNITY, INNATE; INTERFERON REGULATORY FACTOR-1; MICE; MOLECULAR MIMICRY; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; RHABDOMYOSARCOMA; THIAZOLES; TUMOR BURDEN; TUMOR NECROSIS FACTOR-ALPHA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85009765372     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.13849     Document Type: Article

References (38)

1. Huh WW, Skapek SX. Childhood rhabdomyosarcoma: new insight on biology and treatment. Current oncology reports. 2010; 12: 402-410
2. Keller C, Guttridge DC. Mechanisms of impaired differentiation in rhabdomyosarcoma. The FEBS journal. 2013; 280: 4323-4334
3. Dagher R, Helman L. Rhabdomyosarcoma: an overview. The oncologist. 1999; 4: 34-44
4. Malempati S, Hawkins DS. Rhabdomyosarcoma: review of the Children's Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studies. Pediatric blood & cancer. 2012; 59: 5-10
5. Linch M, Miah AB, Thway K, Judson IR, Benson C. Systemic treatment of soft-tissue sarcoma-gold standard and novel therapies. Nature reviews.Clinical oncology. 2014; 11: 187-202
6. Fulda S. Targeting apoptosis resistance in rhabdomyosarcoma. Current cancer drug targets. 2008; 8: 536-544
7. Fulda S. Smac mimetics as IAP antagonists. Seminars in cell & developmental biology. 2015; 39: 132-138
8. Beug ST, Conrad DP, Alain T, Korneluk RG, Lacasse EC. Combinatorial cancer immunotherapy strategies with proapoptotic small-molecule IAP antagonists. The International journal of developmental biology. 2015; 59: 141-147
9. Gyrd-Hansen M, Meier P. IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nature reviews.Cancer. 2010; 10: 561-574
10. Albeck JG, Burke JM, Aldridge BB, Zhang M, Lauffenburger DA, Sorger PK. Quantitative analysis of pathways controlling extrinsic apoptosis in single cells. Molecular cell. 2008; 30: 11-25
11. Beug ST, LaCasse EC, Korneluk RG. Smac mimetics combined with innate immune stimuli create the perfect cytokine storm to kill tumor cells. Oncoimmunology. 2014; 3: e28541
12. Li L, Thomas RM, Suzuki H, De Brabander JK, Wang X, Harran PG. A small molecule Smac mimic potentiates TRAIL-and TNFalpha-mediated cell death. Science (New York, N.Y.). 2004; 305: 1471-1474
13. Faye MD, Beug ST, Graber TE, Earl N, Xiang X, Wild B, Langlois S, Michaud J, Cowan KN, Korneluk RG, Holcik M. IGF2BP1 controls cell death and drug resistance in rhabdomyosarcomas by regulating translation of cIAP1. Oncogene. 2015; 34: 1532-1541
14. Weingartner M, Siegmund D, Schlecht U, Fotin-Mleczek M, Scheurich P, Wajant H. Endogenous membrane tumor necrosis factor (TNF) is a potent amplifier of TNF receptor 1-mediated apoptosis. The Journal of biological chemistry. 2002; 277: 34853-34859
15. Houghton PJ, Kang MH, Reynolds CP, Morton CL, Kolb EA, Gorlick R, Keir ST, Carol H, Lock R, Maris JM, Billups CA, Smith MA. Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program. Pediatric blood & cancer. 2012; 58: 636-639
16. Beug ST, Tang VA, LaCasse EC, Cheung HH, Beauregard CE, Brun J, Nuyens JP, Earl N, St-Jean M, Holbrook J, Dastidar H, Mahoney DJ, Ilkow C, et al. Smac mimetics and innate immune stimuli synergize to promote tumor death. Nature biotechnology. 2014; 32: 182-190
17. Murtas D, Maric D, De Giorgi V, Reinboth J, Worschech A, Fetsch P, Filie A, Ascierto ML, Bedognetti D, Liu Q, Uccellini L, Chouchane L, Wang E, et al. IRF-1 responsiveness to IFN-gamma predicts different cancer immune phenotypes. British journal of cancer. 2013; 109: 76-82
18. Brien JD, Daffis S, Lazear HM, Cho H, Suthar MS, Gale M,Jr, Diamond MS. Interferon regulatory factor-1 (IRF-1) shapes both innate and CD8(+) T cell immune responses against West Nile virus infection. PLoS pathogens. 2011; 7: e1002230
19. Wang C. Childhood rhabdomyosarcoma: recent advances and prospective views. Journal of dental research. 2012; 91: 341-350
20. Fulda S, Vucic D. Targeting IAP proteins for therapeutic intervention in cancer. Nature reviews.Drug discovery. 2012; 11: 109-124
21. Cheung HH, Beug ST, St Jean M, Brewster A, Kelly NL, Wang S, Korneluk RG. Smac mimetic compounds potentiate interleukin-1beta-mediated cell death. The Journal of biological chemistry. 2010; 285: 40612-40623
22. Ascierto ML, De Giorgi V, Liu Q, Bedognetti D, Spivey TL, Murtas D, Uccellini L, Ayotte BD, Stroncek DF, Chouchane L, Manjili MH, Wang E, Marincola FM. An immunologic portrait of cancer. Journal of translational medicine. 2011; 9: 146-5876-9-146
23. Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nature reviews.Drug discovery. 2015; 14: 642-662
24. Kumar S, Ingle H, Mishra S, Mahla RS, Kumar A, Kawai T, Akira S, Takaoka A, Raut AA, Kumar H. IPS-1 differentially induces TRAIL, BCL2, BIRC3 and PRKCE in type I interferons-dependent and-independent anticancer activity. Cell death & disease. 2015; 6: e1758
25. Han ZQ, Assenberg M, Liu BL, Wang YB, Simpson G, Thomas S, Coffin RS. Development of a second-generation oncolytic Herpes simplex virus expressing TNFalpha for cancer therapy. The journal of gene medicine. 2007; 9: 99-106
26. Roesler S, Eckhardt I, Wolf S, Fulda S. Cooperative TRAIL production mediates IFNalpha/Smac mimetic-induced cell death in TNFalpha-resistant solid cancer cells. Oncotarget. 2016; 7: 3709-3725. doi: 10.18632/oncotarget.6915
27. Eytan DF, Snow GE, Carlson SG, Schiltz S, Chen Z, Van Waes C. Combination effects of SMAC mimetic birinapant with TNFalpha, TRAIL, and docetaxel in preclinical models of HNSCC. The Laryngoscope. 2015; 125: E118-24
28. de Vries CR, Kaufman HL, Lattime EC. Oncolytic viruses: focusing on the tumor microenvironment. Cancer gene therapy. 2015; 22: 169-171
29. Francis L, Guo ZS, Liu Z, Ravindranathan R, Urban JA, Sathaiah M, Magge D, Kalinski P, Bartlett DL. Modulation of chemokines in the tumor microenvironment enhances oncolytic virotherapy for colorectal cancer. Oncotarget. 2016 doi: 10.18632/oncotarget.7907
30. Cassady KA, Haworth KB, Jackson J, Markert JM, Cripe TP. To Infection and Beyond: The Multi-Pronged Anti-Cancer Mechanisms of Oncolytic Viruses. Viruses. 2016; 8: 10.3390/v8020043
31. Ilkow CS, Marguerie M, Batenchuk C, Mayer J, Ben Neriah D, Cousineau S, Falls T, Jennings VA, Boileau M, Bellamy D, Bastin D, de Souza CT, Alkayyal A, et al. Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity. Nature medicine. 2015; 21: 530-536
32. Smyth MJ, Ngiow SF, Ribas A, Teng MW. Combination cancer immunotherapies tailored to the tumour microenvironment. Nature reviews.Clinical oncology. 2016; 13: 143-158
33. Highfill SL, Cui Y, Giles AJ, Smith JP, Zhang H, Morse E, Kaplan RN, Mackall CL. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Science translational medicine. 2014; 6: 237ra67
34. Contardi E, Palmisano GL, Tazzari PL, Martelli AM, Fala F, Fabbi M, Kato T, Lucarelli E, Donati D, Polito L, Bolognesi A, Ricci F, Salvi S, et al. CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction. International journal of cancer. 2005; 117: 538-550
35. Callahan MK, Wolchok JD. At the bedside: CTLA-4-and PD-1-blocking antibodies in cancer immunotherapy. Journal of leukocyte biology. 2013; 94: 41-53
36. Chen KF, Lin JP, Shiau CW, Tai WT, Liu CY, Yu HC, Chen PJ, Cheng AL. Inhibition of Bcl-2 improves effect of LCL161, a SMAC mimetic, in hepatocellular carcinoma cells. Biochemical pharmacology. 2012; 84: 268-277
37. Stojdl DF, Lichty BD, tenOever BR, Paterson JM, Power AT, Knowles S, Marius R, Reynard J, Poliquin L, Atkins H, Brown EG, Durbin RK, Durbin JE, et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer cell. 2003; 4: 263-275
38. Holcik M, Lefebvre CA, Hicks K, Korneluk RG. Cloning and characterization of the rat homologues of the Inhibitor of Apoptosis protein 1, 2, and 3 genes. BMC Genomics. 2002 3: 5-10